+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 2Years - 99Years
All Genders
ID05090891

Evaluation of INCB000928 for Safety and Effectiveness in Fibrodysplasia Ossificans Progressiva Using a Randomized, Double-Blind, Placebo-Controlled Design

Led by Incyte Corporation · Updated on 2026-10-22

98

Participants Needed

24

Research Sites

285 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy, safety, and tolerability of a drug called INCB000928 in people diagnosed with fibrodysplasia ossificans progressiva FOP, a rare condition. This Phase 2, randomized, double-blind, placebo-controlled trial aims to understand how well INCB000928 works and its pharmacokinetics in different age groups with FOP. The study is sponsored by Incyte Corporation and focuses on treatment outcomes over several years. Participants are divided into three age cohorts 12 years and older, 6 to under 12 years, and 2 to under 12 years after safety review. They receive either INCB000928 or a placebo orally once daily for 24 weeks during the double-blind period. After completing this period, participants may continue in an open-label extension phase lasting an additional 292 weeks, where all receive INCB000928. During the study, participants will undergo low-dose whole-body CT scans excluding the head to monitor new heterotopic ossification lesions. Researchers will measure the number and volume of new lesions and record any new flare-ups. Pharmacokinetics of the drug will be assessed at multiple time points. Safety is closely monitored throughout, including adverse events, with total participation potentially lasting over six years.

CONDITIONS

Brief Title

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Research Team

I

Incyte Corporation Call Center (US)

I

Incyte Corporation Call Center (ex-US)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here